UK Pharma Industry Warns of Declining Competitiveness
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the…
The latest from Brazilian Pharma, including the controversial proposal to transform Brazil’s regulatory agency, ANVISA; Ease Labs’s canabidiol approval, Biolab’s international expansion ambitions and Eurofarma’s multiple myeloma deal. ANVISA’s…
Despite an uncertain macro-economic environment, the French health technology sector continues its growth trajectory, demonstrating both entrepreneurial dynamism and maturity, according to the new edition of the France Biotech study…
With the passage of the US Inflation Reduction Act (IRA) that will begin to take effect this year, the biopharma industry continues to grapple with the implications of the new…
Poland’s largest pharmaceutical company and leading generics manufacturer, Polpharma, is looking to expand its presence outside of the country’s borders. With a recent acquisition bid for former Sanofi European generics…
With the global market for generic drugs expected to reach USD 36.4 billion by 2027 and grow at a CAGR of 5.6 percent over the period 2020-2027, it is not…
During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in…
A roundup of some of the biggest pharma news from Belgium including Neuraxpharm’s new Belgian affiliate, Novalis Biotech’s investment in Rarity Bioscience, Catalent’s plasmid DNA manufacturing site and a recent…
In the five years since the Japanese drugmaker began a strategic shift and created an ambitious plan to maintain growth, CEO Kenji Yasukawa helped Astellas move away from its previous…
A roundup of some of the biggest pharma and biotech news from China including the approval of two domestically developed COVID treatments; Daewoong’s idiopathic pulmonary fibrosis licensing deal, Roche’s gastric…
See our Cookie Privacy Policy Here
